Last update Dec. 10, 2022
Antispasmodic drug with antimuscarinic and weak opioid agonist effects used for treatment of Irritable Colon Syndrome and in the treatment of infant and young child vomiting (Pediamecum 2015). Oral administration.
At latest update, no relevant published data concerning excretion into breast milk were found.
Side effects of Trimebutine are rare and generally mild. (CADTH 2015, Paquette 2014)
Authorized use in some countries during the neonatal and infant period. (Pediamecum 2015, Carnot 2008)
Although antimuscarinics can decrease prolactin production (Müller 1983, Masala 1982), once lactation is established, milk production depends more on the repeated stimulation of suckling than on prolactin levels.
In 2017, a mother reported to us a complete decrease in milk production when taking trimebutine (time and dose not reported).
Occasional use and at a sufficient minimum dose may be compatible with breastfeeding. Monitor drowsiness and milk production. Do not use it soon after birth or in case of premature infant.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM